bluebird bio Company Profile

Description

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Its product candidates include Lenti-D, which is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder; and LentiGlobin that is in phase I/II clinical studies for the treatment of beta-thalassemia major and severe sickle cell disease (SCD) in France, as well as a phase I study in the United States for the treatment of severe SCD. The company’s lead chimeric antigen receptor T cell-based product candidate is bb2121, which is in phase I clinical trials for the treatment of relapsed and refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Kite Pharma, Inc. to develop and commercialize second generation T cell receptor product candidates against the human papillomavirus type 16 E6 oncoprotein. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.